Skip to Main Content

Relay Therapeutics will present data at a medical meeting Friday that give investors and oncologists the first look at RLY-4008, its drug to treat a form of liver cancer.

“So far in the clinic, 4008 has done everything we designed it to do from the outset,” Don Bergstrom, Relay’s chief medical officer, told STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment